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Introduction {#sec001}
============

*Acinetobacter baumannii* has been established as one of the leading nosocomial pathogens worldwide. It causes a spectrum of diseases which affects the following areas: the respiratory tract, the bloodstream, the surgical site, wound infections and the urinary tract \[[@pone.0209425.ref001]\]. An increasing number of nosocomial infections caused by this pathogen, particularly bacteremia and pneumonia were noted worldwide among patients admitted to Intensive Care Units (ICUs) \[[@pone.0209425.ref002]\]. Such infections might be associated with considerably increased mortality rates (52% and 34.1% respectively) \[[@pone.0209425.ref003],[@pone.0209425.ref004]\].

*A*.*baumannii* is one of the most difficult acquired pathogens to control at ICUs because of both its ability to survive in hospital environments and its capacity ofacquiring genes resistance rapidly by different mechanisms including plasmids, transposons and integrons' acquisition \[[@pone.0209425.ref005]\]. The most common antimicrobial resistance reported in *A*. *baumannii* is towards carbapenem \[[@pone.0209425.ref006]\]. The acquired carbapenem resistance is often associated with the OXA-type carbapenemases and metallo-β-lactamases \[[@pone.0209425.ref007]\]. This bacterium has also an intrinsic production of beta-lactamases with carbapenemases properties \[[@pone.0209425.ref008]\].

Episodes of *A*. *baumannii* infection have been reported as clustered epidemics with contamination of environmental sources or transmission from hand to hand of health care workers, which ultimately lead to colonization or subsequent infection of patients \[[@pone.0209425.ref009]\]. Different mechanisms of MDR *A*. *baumannii* acquisition were reported such as cross-transmissions, comorbidities, antibiotic treatment duration including carbapenems therapy, environment and severity of acute illness \[[@pone.0209425.ref008]\]. Moreover, prior colonization with *A*.*baumannii* has been found to be a risk factor for neonatal infections \[[@pone.0209425.ref010]\].

As is the case of a lot of countries, this bacterium is frequently isolated in Moroccan hospitals \[[@pone.0209425.ref011]\]. This study is the first of its kind to highlight the intestinal MDR *A*. *baumannii* carriage and its resistance to antibiotics as seen in newborns in Moroccan NICU. Therefore, we performed this prospective observational study to determine the prevalence of nosocomial acquisition of multidrug-resistant *A*. *baumannii* intestinal carriage amongst neonates in Moroccan NICU. Carriage rate at admission, risk factors of colonization, resistance profiles and genotypic characteristics were also studied.

Methods {#sec002}
=======

Study design {#sec003}
------------

This prospective study was conducted at the service of neonatology and intensive care unit of the University Hospital of Fez (Morocco). The hospital setting is a medical and surgical NICU that has 18 beds divided into 2 sectors (9 beds for each one); sector 1 corresponds to an intensive care unit and sector 2 corresponds to a preterm baby unit. This NICU is the only one in Fez, a city with an estimated population of approximately 1.5 million inhabitants. Despite the fact that the hand-hygiene compliance was not monitored in our NICU, standard hygiene precautions were nevertheless respected, such as hand hygiene before and after each contact with a patient and the surrounding surfaces, and contact isolation precautions with gloves for proven cases of carriage with *A*. *baumannii* as well as for patients colonized with multi-drug-resistant bacteria. The most common empiric antibiotic regimen in case of clinical suspicion of nosocomial sepsis was imipenem for the coverage of *A*. *baumannii*.

Patient's selection {#sec004}
-------------------

The patient's selection is from February 2013 to July 2015 and, all consecutive neonates admitted into the unit are also included. Only the first NICU admission per neonate was examined in the analysis. Babies were evaluated for *Acinetobacter baumannii* intestinal carriage at admission (a) and *Acinetobacter baumannii* acquisition during hospitalization (b). Imported carriers were excluded from the acquisition analysis to take into account just babies who acquired *A*. *baumannii* during their NICU stay. Furthermore, those without follow-up samples (due to death or discharge before the scheduled follow-up sampling) were excluded.

Ethical approval {#sec005}
================

This study was approved by the Joint Research Ethics Committee of Medical School and university Hospital Hassan II of Fez (Fez, Morocco). Written information about the nature of the experimental procedures was given to parents of patients, who were asked for their consent.

Statistical analysis {#sec006}
--------------------

Potential risk factors associated with *A*. *baumannii* colonization were studied. The socio-demographic and clinical characteristics of patients were collected prospectively using a standard written questionnaire. Statistical analysis was carried out using SPSS, version 20 (SPSS Inc., Chicago, IL, USA) software. Results for quantitative variables were presented as mean ± standard deviation and for qualitative variables as number (percentage). Then, an univariate analysis was performed to establish all associations between gender, age, birth weight, prematurity, birthplace, admission and birth route, date of hospitalization, NICU admission and diagnosis after NICU admission. During NICU hospitalization, antimicrobial therapy, breastfeeding, central or peripheral venous catheterization and length of hospital stay were also recorded in the questionnaire. Chi-square test and Fisher's exact test were used to established significant association when appropriate. The *P* \< 0.05 was deemed as statistically significant. The multivariate analysis was performed to identify a potential risk factor associated with intestinal MDR *A*. *baumannii* colonization using simple logistic regression analysis. All variables with p\<0.2 in an univariate analysis were included in a logistic regression model for a multivariate analysis. Odds ratios were presented with the corresponding 95% confidence intervals (OR, CI 95%).

Sampling and screening {#sec007}
----------------------

Two rectal swabs were collected from each newborn. The initial sample was performed up to 6 hours from admission to the NICU and the second one after 5 days of hospitalization in order not to lose patients in this schedule screening. Rectal swab specimens were enriched in nutrient broth BHI (Brain Heart infusion, Oxoid) at 37°C for 24h. Then, they were inoculated on Mac Conkey agar plates and incubated at 37°C for 24h. The identification of *A*. *baumannii* isolates was performed by classical bacteriological techniques (Gram stain, Oxidase test and Fermentation Glucose test) and confirmed by using API 20 NE galleries (Biomérieux, Marcy l'Etoile, France). Strains were originally identified as *Acinetobacter baumannii-calcoaceticus* complex and *A*. *baumannii* species confirmation was performed by *bla*~*OXA-51*~ gene PCR amplification.

Antimicrobial susceptibility testing {#sec008}
------------------------------------

As recommended by the EUCAST 2013, the following antimicrobial agents (Oxoid) were tested to evaluate susceptibility by disk diffusion method: Ticarcillin TIC (75 μg), Ceftazidime CAZ (30μg), Piperacillin PEP (75μg), Piperacillin/Tazobactam PTZ (75/10μg), Imipenem IMP (10μg), Gentamicin GN (10μg), Amikacin AK (30μg), Tobramycin TOB (10μg), Ciprofloxacin CIP (5 μg) and Trimethoprim/Sulfamethoxazole SXT (1.25/23.75μg). Isolates of resistant *A*. *baumannii* to three or more classes of antibiotics were considered as MDR (6) and those ones with an inhibition zone \<17mm were treated as resistant to imipenem. The modified Hodge test and the Ethylene-Diamine-Tetra-Acetic (EDTA) disk synergy test were performed to screen for carbapenemase production. A difference of inhibition zone diameter \>5 mm between imipenem disks and imipenem plus EDTA was interpreted as metallo-β-lactamase MBL positive. All resistant strains to Imipenem were screened by conventional single-plex PCR assay for the following carbapenemases encoding genes: *bla*~*OXA-23*,~ *bla*~*OXA-24*,~ *bla*~*OXA-51*,~ *bla*~*OXA-58*,~ *bla*~*KPC*,~ *bla*~*NDM*,~ *bla*~*IMP*~ and *bla*~*VIM*~.

Preparation of DNA template for PCR {#sec009}
-----------------------------------

The total DNA was extracted by suspending few colonies of an overnight culture of *A*. *baumannii* isolates in 500 μL of DNase- and RNase-free water (Invitrogen, Paisley, UK). The suspension was boiled at 100°C for 10 min in a thermal block (Polystat 5, Bioblock Scientific, France), then centrifuged at 14000 x *g* for 10 min. An aliquot of 2 μL of the supernatant was used as a DNA template for PCR.

Detection of carbapenemases encoding genes {#sec010}
------------------------------------------

Amplification reactions to detect carbapenemases encoding genes were performed in a volume of 50 μL containing, 2 μL of DNA template, 2.5mM MgCl~2~, 0.4μM of each forward and reverse primers, 100 μM of each dNTP, and 2 units *Taq* DNA polymerase (Promega, Madison, USA) in 1X PCR buffer provided by the manufacturer's instructions. The amplification conditions were described previously \[[@pone.0209425.ref012],[@pone.0209425.ref013]\]. Known carbapenemase producing strains were used as positive controls. PCR products were detected on 1% agarose gel (FMC Bioproduct, Rockland, ME) after ethidium bromide staining, UV illumination and photographed by an Olympus digital camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany).

Results {#sec011}
=======

During the study period, 455neonates were screened. The average gestational age and mean birth weight were 35.2 (±3.2) weeks and 2612.1 g (±1023.2) respectively.

Of 455 patients screened for *A*. *baumannii*, 45 were carriers at NICU admission (9.8%). These patients were excluded from acquisition analysis. The remaining 90.2% (410 babies) were evaluated for *A*. *baumannii* acquisition. Of these, 133 (32.4%) patients were excluded, as they had no follow-up samples: 94 were discharged and 39 died before the planned sampling.

Finally, 277/455 (60.8%) were evaluated for *A*. *baumannii* acquisition. Twenty-nine (13.7%) out of 277 newborns had acquired *A*. *baumannii* in our NICU with a mean age of 9±7.2 days (S.D. Standard Deviation).

*Baumannii* intestinal carriage {#sec012}
-------------------------------

On the day of admission, the prevalence of *A*. *baumannii* rectal carriage was 9.8% (45/455), 30 babies had MDR *A*. *baumannii* (6.5%) and 6 had Carbapenemase producing (CP) *A*. *baumannii* (1.3%). Overall admission carriers, 68% were males (31/45), 71% were \<48h old (32/45), 75% were born in the UH maternity unit (34/45), 62% came directly from the UH maternity unit to NICU (28/45) and 53.5% were \< 24h old \[[Table 1](#pone.0209425.t001){ref-type="table"}\].

10.1371/journal.pone.0209425.t001

###### Association between patient's characteristics and prevalence of multidrug-resistant *A*.*baumannii* carriage at the day of admission and during hospitalization at NICU.

![](pone.0209425.t001){#pone.0209425.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   At admission    During NICU stay                                                                 
  ------------------------------------------------ --------------- ------------------ ----------- ----------- -------------- ----------- ---------- -----------
  Gender                                                                                                                                            

   Male                                            267(58.7)       244 (57.4)         23 (76.7)   **0.028**   162(58.5)      139(58.2)   23(60.5)   0.783

   Female                                          188(41.3)       181 (42.6)         7 (23.3)    115(41.5)   100(41.8)      15(39.5)               

  Age (days)                                                                                                                                        

   0--2                                            Mean±S.D.\      290 (68.2)         18 (60)     0.200       Mean±S.D\      155(64.9)   32(84.2)   **0.018**
                                                   6.5±15.8 days                                              6.2±15 days                           

   \> 2                                            135 (31.8)      12 (40)            84(35.1)    6(15.8)                                           

  Prematurity                                                                                                                                       

   Yes                                             223(49)         205 (48.2)         18 (60)     0.145       142(51.3)      117(49)     25(65.8)   0.054

   No                                              232(51)         220 (51.7)         12 (40)     135(48.7)   122(51)        13(34.2)               

  Birth weight (g)                                                                                                                                  

   \< 2500                                         Mean±S.D.\      207 (48.7)         19 (63.3)   0.087       Mean±SD\       116(48.5)   24(63.2)   0.094
                                                   2612±1023g                                                 2542±1020g                            

   ≥ 2500                                          218 (51.3)      11 (36.7)          123(51.5)   14(36.8)                                          

  Pathology[\*](#t001fn001){ref-type="table-fn"}                                                                                                    

   Respiratory distress                            259(56.9)       240 (52.7)         19 (63.3)   0.296       160(57.8)      132(55.2)   28(73.7)   **0.032**

   Icterus                                         38(8.4)         35 (8.2)           3 (10)      0.467       22(7.9)        21(8.8)     1(2.6)     0.192

   Surgical pathology                              31(6.8)         31 (7.3)           0 (0)       0.112       21(7.6)        19(7.9)     2(5.3)     0.561

   Neonatal suffering                              34(7.5)         32 (7.5)           2 (6.7)     0.608       18(6.5)        16(6.7)     2(5.3)     0.740

   Neonatal infections                             35(7.7)         31 (7.3)           4 (13.3)    0.191       19(6.5)        16(6.7)     3(7.9)     0.786

   Neurological distress                           44(9.7)         42 (9.9)           2 (6.7)     0.428       30(10.8)       26(10.9)    4(10.5)    0.948

   Congenital malformations                        11(2.4)         11 (2.6)           0 (0)       0.468       6(2.2)         6(2.5)      0(0)       0.323

   Others                                          49(11.8)        47 (11.1)          2 (6.7)     0.351       24(8.7)        22(9.2)     2(5.3)     0.422

  Birthplace                                                                                                                                        

   Maternity of UH Fez                             265(58.2)       241 (56.7)         24 (80)     **0.043**   152(54.9)      128(53.6)   24(63.2)   0.369

   Other hospitals                                 164(36)         159 (37.4)         5 (16.7)    105(37.9)   92(38.5)       13(34.2)               

   Home                                            26(5.7)         25 (5.9)           1 (3.3)     20(7.2)     19(7.9)        1(2.6)                 

  Admission route                                                                                                                                   

   Maternity of UH Fez                             236(51.8)       217 (51.1)         19 (63.3)   0.404       137(49.5)      112(46.9)   25(65.8)   **0.010**

   Other hospitals                                 124(27.3)       119 (28)           5 (16.6)    83(30)      71(29.7)       12(31.6)               

   Home                                            95(20.8)        89 (20.9)          6 (20)      57(20.6)    56(23.4)       1(2.5)                 

  Birth route                                                                                                                                       

   Vaginal                                         310(68.1)       291 (68.5)         19 (63.3)   0.345       196(70.8)      174(72.8)   22(57.9)   0.061

   Caesarean section                               145(31.9)       134 (31.5)         11 (36.7)   81(92.2)    65(27.2)       16(42.1)               

  Length of stay (days)                                                                                                                             

   \< 3                                            \--             \--                \--         \--         Mean±S.D\      17(7.1)     1(2.5)     0.298
                                                                                                              8.9±7.2 days                          

   ≥ 3                                             \--             \--                222(92.9)   37(94.4)                                          

  Venous catheterization                                                                                                                            

   Peripheral                                      \--             \--                \--         \--         272(98.2)      234(97.9)   38(100)    0.362

   Central                                         \--             \--                \--         5(1.8)      5(2.1)         0(0)                   

  Breastfeeding                                                                                                                                     

   Breastfed newborn                               \--             \--                \--         \--         97(35)         88(36.8)    9(23.7)    0.115

   Diet newborn                                    \--             \--                \--         180(65)     151(63.2)      29(76.3)               

  Antibiotherapy                                                                                                                                    

   Ceftriaxon+Gentamicin                           \--             \--                \--         \--         166(59.9)      143(59.8)   23(60.5)   0.935

   Amoxicillin+Gentamycin                          \--             \--                \--         87(31.4)    73(30.5)       14(36.8)    0.437      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Neonates may have more than one reason for hospitalization;

AB: *A*. *baumannii*

During NICU stay, the prevalence of *A*.*baumannii* intestinal acquisition was 14% (39/277). Thirty eight newborns had MDR *A*. *baumannii*(13.7%) and three had CP *A*. *baumannii*(1%). About 84% of babies acquired *A*.*baumannii* when they were \< 48h old at the time of admission (32/39), 73% had respiratory distress as reason for hospitalization (28/39) and 65% were premature (25/39). The clinical characteristics of the patients are summarized in [Table 1](#pone.0209425.t001){ref-type="table"}.

Risk factors {#sec013}
------------

Characteristics significantly found to be associated with MDR *A*. *baumannii* carriage at admission were the following: male gender (P = 0.028) and birthplace (P = 0.043). In fact, 24 carriers of MDR *A*. *baumannii* were born at the UH maternity unit (80%). 18 neonates of them came directly from the UH maternity unit to NICU. On the other hand, male gender was also associated with MDR *A*. *baumannii* carriage and the majority of carriers were male (76.7%).

Statistical analysis showed that there was a significant difference between newborns who had acquired and those who had not acquired MDR *A*. *baumannii* with regard to the age (p = 0.01), prematurity (p = 0.05), respiratory distress (p = 0.03) and admission route (p = 0.01) \[[Table 1](#pone.0209425.t001){ref-type="table"}\].

In a multivariate analysis, gender (OR, 0.382; 95% CI, 0.158 to 0.921; P = 0.03), age at NICU admission (OR, 2.803; 95% CI, 1.191 to 6.596; P = 0.01) and birth in the UH maternity unit (OR, 0.196; 95% CI, 0.071 to 0.540; P = 0.002) were statistically associated with carriage at admission. Furthermore, the respiratory distress was the single factor found associated with acquisition of MDR *A*. *baumannii*(OR, 2.270; 95% CI, 1.055 to 4.881; P = 0.03)\[[Table 2](#pone.0209425.t002){ref-type="table"}\].

10.1371/journal.pone.0209425.t002

###### Multivariable analysis of MDR A. baumannii carriage at NICU admission and acquisition during hospitalization.

![](pone.0209425.t002){#pone.0209425.t002g}

  Variable                   Multivariable analysis for *A*.*baumannii* carriage at NICU admission   Multivariable analysis for *A*. *baumannii* acquisition                          
  -------------------------- ----------------------------------------------------------------------- --------------------------------------------------------- ---------------------- -------
  **Gender**                 0.382 (0,158--0.921)                                                    0,032                                                     \-                     \-
  **Age**                    2,803 (1,191--6,596)                                                    0,018                                                     \-                     \-
  **Birth place**            0.196 (0,071--0,540)                                                    0,002                                                     \-                     \-
  **Respiratory distress**   \-                                                                      \-                                                        2,270 (1,055--4.881)   0.036

Antibiotic resistance of *A*. *baumannii* isolates {#sec014}
--------------------------------------------------

A total of 84 *A*. *baumannii* isolates were collected: 53.5% at admission (n = 45) and 46.4% at discharge (n = 39). The majority of *A*. *baumannii* isolates (admission and discharge combined isolates) showed an MDR phenotype (68/84). More than 92% of isolates were resistant to PEP, TIC, TCA, CAZ, TOB, GN and CIP (77/84). Resistance rate for PTZ, SXT, AK and IMP were lower (ranged from 3--36%). In addition, 72.6% of isolates share the same antimicrobial resistance profile (61/84) as being resistant to PEP, TIC, TCA, CAZ, TOB, GN and CIP. However, each strain could be phenotypically distinguished if we took into consideration its susceptibility to the other antimicrobials tested.

At admission, all MDR *A*. *baumannii* isolates were resistant to PEP, TIC, TOB and GN (100%). Most of them exhibited resistance to TCA, CAZ and CIP (96%). During hospitalization, all MDR *A*. *baumannii* acquired isolates were resistant to CAZ and PEP (100%). Resistance rates range between 92--96% for TIC, TCA, TOB, GN and CIP \[[Table 3](#pone.0209425.t003){ref-type="table"}\].

10.1371/journal.pone.0209425.t003

###### Susceptibility patterns of the 69 isolated MDR *A*. *baumannii* strains.

![](pone.0209425.t003){#pone.0209425.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotics                     Nr. of AB isolates\   Nr. of MDR-AB isolates\   Nr. of MDR-AB carriers\                          
                                  \[N (%)\]             \[N (%)\]                 \[N (%)\]                                        
  ------------------------------- --------------------- ------------------------- ------------------------- ----------- ---------- ------------
  Pepiracillin/Tazobactam         8 (17.7)              14 (35.8)                 8 (26.6)                  14 (36.8)   8 (1.7)    14 (5.04%)

  Pepiracillin                    30 (66.6)             38 (97.4)                 30 (100)                  38 (100)    30 (6.5)   38 (13.7)

  Ticarcillin                     30 (66.6)             36 (92.3)                 30 (100)                  36 (94.7)   30 (6.5)   36 (12.9)

  Ticarcillin/Clavulanic Acid     29 (64.4)             36 (92.3)                 29 (96.6)                 36 (94.7)   29 (6.3)   36 (12.9)

  Ceftazidim                      29 (64.4)             38 (97.4)                 29 (96.6)                 38 (100)    29 (6.3)   38 (13.7)

  Imipenem                        6 (13.3)              3 (7.69)                  6 (20)                    3 (7.8)     6 (1.3)    3 (1)

  Tobramycin                      30 (66.6)             37 (94.8)                 30 (100)                  37 (97.3)   30 (6.5)   37 (13.3)

  Amikacin                        1 (2.2)               7 (17.9)                  1 (3.3)                   7 (18.4)    1 (0.2)    1 (0.3)

  Gentamycin                      30 (66.6)             37 (94.8)                 30 (100)                  37 (97.3)   30 (6.5)   30 (10.8)

  Ciprofloxacin                   29 (64.4)             35 (89.7)                 29 (96.6)                 35 (92.1)   29 (6.3)   35 (12.6)

  Trimethoprim/Sulfamethoxazole   3 (6.6)               5 (12.8)                  3 (10)                    5 (13.1)    3 (0.6)    5 (1.8)
  ---------------------------------------------------------------------------------------------------------------------------------------------

AB: *A*. *baumannii*

Concerning imipenem resistance, 13.3% of MDR isolates were imipenem resistant (9/68), 20.5% were intermediate (14/68) and 66.2% were susceptible (45/68).

The Hodge test was positive for all isolates resistant to imipenem. Similarly, tests with IMP and IMP/EDTA indicated the presence of an MBL in these isolates.

Molecular analysis of CP *A*. *baumannii* isolates using PCR {#sec015}
------------------------------------------------------------

Among all imipenem resistant isolates, the resistance genes *bla*~*OXA-23*,~ *bla*~*OXA-24*,~ *bla*~*OXA-51*,~ *bla*~*OXA-58*,~ *bla*~*KPC*,~ *bla*~*NDM*,~ *bla*~*IMP*~ *and bla*~*VIM*~ had been investigated. The PCR results showed that all our isolates (100%) were positive for *bla*~*OXA-51*~ gene(n = 84), confirming the identification of *A*.*baumannii* species. Besides, 8 out of 9 CP *A*. *baumannii* isolates were positive for *bla*~*OXA-23*~ encoding gene. However, no strain had *bla*~*OXA-24*~ and *bla*~*OXA-58*~ genes in its genome. Likewise, PCRs for *bla*~*KPC*~, *bla*~*IMP*~, *bla*~*VIM*~ and *bla*~*NDM*~ were negative.

Discussion {#sec016}
==========

Colonization by MDR *A*. *baumannii* in a hospital is a serious concern worldwide, mainly because of limited therapeutic options for treating infections caused by this resistant pathogen. It was listed as one of the six top-priority dangerous microorganisms by the *Infectious Diseases Society of America* (IDSA) \[[@pone.0209425.ref014]\].

To the best of our knowledge, this is the first study in Morocco to focus on MDR *A*. *baumannii* intestinal carriage among babies during hospitalization at the NICU. The prevalence rate of *A*.*baumannii* acquisition was 14% in our study and almost all of the isolates were MDR (97%). A previous study performed in 2011 in France showed that 11% of hospitalised patients acquired MDR *A*. *baumannii* \[[@pone.0209425.ref015]\]. On the other hand, the main finding of our study was the prevalence of neonates colonization on admission which was 9.8% with more than 66% of MDR (6.5%). Our prevalence was lower than a previous study made in Spain (25%) and similar to an American one (8.7%) \[[@pone.0209425.ref016],[@pone.0209425.ref017]\]. Recent study in Taiwan, found just 0.2% of *A*. *baumannii* intestinal carriage from ICU admitted patients \[[@pone.0209425.ref018]\]. Furthermore, mouth/throat, skin and rectal swabs samples in a Turkish ICU revealed that 6.3% of adults hospitalised were colonized by *A*.*baumannii* on admission \[[@pone.0209425.ref019]\].

This study also proves that birth at a UH maternity unit is a risk factor for MDR *A*. *baumannii* carriage. However, insufficient incubators in our NICU can prolong the length of stay at the UH maternity unit, which could explain, in part the colonization by MDR *A*. *baumannii*. Also, the lack of hygienic practices during delivery and postnatal care can promote this colonization during the first week of baby's life \[[@pone.0209425.ref020]\]. During hospitalization, respiratory distress was the single risk factor of MDR *A*. *baumannii* acquisition found (OR, 2.270; 95% CI, 1.055 to 4.881; P = 0.03). Cisneros-Herreros *et al*. \[[@pone.0209425.ref021]\] have reported that acute respiratory distress syndrome is a risk factor for *A*. *baumannii* nosocomial pneumonia in ICU. More than 80% of infected patients were associated with mechanical ventilation \[[@pone.0209425.ref022]\]. The long duration of the mechanical ventilation has been reported by Zhang *et al*. \[[@pone.0209425.ref023]\] as a risk factor.

Prematurity, early age and the admission route of babies were also reported as parameters that increase dramatically the risk of acquisition and/or infection by MDR *A*. *baumannii* in the NICU \[[@pone.0209425.ref024],[@pone.0209425.ref025]\]. In our univariate analysis, these factors were significantly associated with acquisition of this bacterium. Likewise, the very low birth weight of babies in the NICUs increases the colonization risk with nosocomial *A*.*baumannii* strains \[[@pone.0209425.ref026]\]. This variable had a tendency to be more associated with case patients, but the values did not reach any statistical significance. The length of stay in the ICU was reported as a risk factor of acquisition of MDR *A*. *baumannii* in several previous studies \[[@pone.0209425.ref010],[@pone.0209425.ref027]\], but it was not significant in ours. A possible reason might be that for fear of losing patients we performed the discharge screening within the space of 5 days.

A very high resistance rate to commonly used antibiotics such as [third-generation cephalosporin](https://www.ncbi.nlm.nih.gov/pubmed/7791418) or gentamicin has been observed among our isolates. The prevalence of intestinal colonization by imipenem resistant *A*. *baumannii* from our NICU was 1%. The same rate was reported in France and Turkey \[[@pone.0209425.ref028],[@pone.0209425.ref029]\]. The prevalence of acquired CP *A*. *baumannii* reported by Playford EG *et al*. was more important (4.5%) \[[@pone.0209425.ref030]\]. The genotyping results of our CP *A*. *baumannii* isolates confirmed the *A*. *baumannii* species through the presence of the intrinsic encoding gene *bla*~*OXA-51*~ and across; thanks to this specific character, we can differentiate between *A*. *baumannii* and other species of *A*. *calcoaceticus-baumannii* complex \[[@pone.0209425.ref031]\]. This gene was detected in all our CP *A*. *baumannii* (100%) and needs to be regulated upstream by IS*Aba1* to provide resistance \[[@pone.0209425.ref032]\]. In other surveys, the prevalence of *bla*~*OXA-51*~ gene was ranged between 80--100% \[[@pone.0209425.ref033],[@pone.0209425.ref034]\]. Then, *bla*~*OXA-23*~ encoding gene was present in 89% of our isolates (8/9). Moreover, it was the main gene responsible of CP *A*. *baumannii*. It is either located on the chromosome or on plasmids and associated with four different genetic structures, with the most frequent being transposons *Tn*2006 \[[@pone.0209425.ref035]\]. Besides, it was the most prevalent carbapenemase-encoding gene circulating in the Mediterranean region \[[@pone.0209425.ref036]\]. A previous Moroccan research study detected *bla*~*OXA-23*~ *bla*~*OXA-51*~, *bla*~*OXA-24*~ and *bla*~NDM~ \[[@pone.0209425.ref037]\]. In the present work, no metallo-β-lactamase genes (*bla*~*IMP*~, *bla*~*VIM*~ and *bla*~*NDM*~) were detected in any of the *A*. *baumannii* isolates. The prevalence of these genes is generally low within *A*. *baumannii* strains isolated from ICUs \[[@pone.0209425.ref038]\] or absent in *A*. *baumannii* intestinal carriage strains in ICUs \[[@pone.0209425.ref028],[@pone.0209425.ref039],[@pone.0209425.ref040]\]. The *bla*~*KPC*~ gene had not been detected either. This gene has been identified worldwide in *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolates \[[@pone.0209425.ref041],[@pone.0209425.ref042]\] and, to date, KPC-producing *A*. *baumannii* has been reported only in Puerto Rico \[[@pone.0209425.ref043]\].

Finally, the prevention of MDR *A*. *baumannii* colonization in newborns is clearly difficult. Screening on admission allows early detection and limits dissemination of these strains with application of appropriate control measures. Implementation of barrier precautions for patients presenting identified risk factors would probably be useful in reducing the cross-transmission between neonates who are the most likely to be colonized. As is the case in most developing countries, a low awareness of hand hygiene practices among health-care professionals was observed in our ward. This NICU is unique in the region of Fez and provides facilities to more than 1200 patients per year. But this ward also is suffering from a lack of sufficient medical staff including 3 seniors and 6 nurses for 18 beds. Moreover, barrier precautions are time consuming and our ward has only a few single rooms. This situation only amplifies the risk of transmission and dissemination of epidemic strains.

There are several limitations to the current study. Firstly, the moment of discharge screening can lead to biased estimates of the association between length of stay and MDR *A*. *baumannii* acquisition. Secondly, since active surveillance for *A*. *baumannii* was not consistent throughout the study period, all admitted patients may not have been included in this study. Lastly, the evaluation of the clonal relationship between the different *A*.*baumannii* isolates was not performed to confirm the role of cross-transmission of these bacteria between patients.

Conclusion {#sec017}
==========

This study showed high prevalence of *A*. *baumannii* intestinal carriage, multiple antibiotic resistance profiles and diversity of encoding genes in our NICU. This situation required development of antimicrobial stewardship initiatives and maintaining of antimicrobial resistance surveillance systems. Furthermore, the knowledge of risk factor profiles may lead to develop strategies of colonization prevention and subsequent invasive disease in high risk hospitalized neonates.
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